Veracyte Inc. reported new data showing its Decipher Prostate genomic classifier can help to identify patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are more likely to benefit from treatment with Erleada (apalutamide) in addition to androgen-deprivation therapy (ADT). The study is the first to demonstrate Decipher Prostate’s prognostic utility in men with locally advanced prostate cancer.
Janssen Pharmaceutica NV and Exelixis Inc. are among the many companies releasing new data ahead of the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which runs Feb. 11-13.
New data show Johnson & Johnson’s Erleada (apalutamide) and Xtandi (enzalutamide) from Pfizer Inc. and Astellas Pharma Inc. both prolonged overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC).